---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-301426"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:52:46.769713+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcellx and Kite (Gilead) partner on CART-ddBCMA; $225M upfront + $100M equity; 100% ORR in Phase 1

## Summary
- Arcellx receives $225M upfront cash and $100M equity investment from Gilead; eligible for up to $3.9B in milestones.
- Phase 1 trial: 100% ORR (38 pts), 71% CR/sCR, 80% CR/sCR in patients dosed >12 months ago; no Grade≥3 CRS at RP2D.
- Kite to manufacture after tech transfer; 50/50 U.S. profit split; low-to-mid teen royalties ex-U.S.; deal expected to close Q1 2023.
- Gilead purchases 3,478,261 shares at $100M; standstill and registration rights agreed.
- iMMagine-1 Phase 2 pivotal trial initiated; Phase 1 trial of ACLX-002 for AML/MDS also started.

## SEC filing metadata
- accession: 0001193125-22-301426
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/0001193125-22-301426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/d420020d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-301426
- JSON: https://secwatch.observer/filing/0001193125-22-301426.json
- Plain text: https://secwatch.observer/filing/0001193125-22-301426.txt

## Key facts
- Material Agreements
  Arcellx, Inc. entered into Collaboration Agreement with Kite Pharma, Inc., a Gilead Company valued at $225 million upfront cash payment (effective 2022-12-09).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Kite Pharma, Inc., a Gilead Company
  - Value: $225 million upfront cash payment
  - Effective: 2022-12-09
  source text: On December 9, 2022, Arcellx, Inc. (“Arcellx”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Kite Pharma, Inc., a Gilead Company (“Kite”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/0001193125-22-301426-index.htm
- Material Agreements
  Arcellx, Inc. entered into Common Stock Purchase Agreement with Gilead Sciences, Inc. valued at $100 million (effective 2022-12-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Gilead Sciences, Inc.
  - Value: $100 million
  - Effective: 2022-12-09
  source text: pursuant to which Arcellx agreed to issue and sell, and Gilead has agreed to purchase, 3,478,261 shares of Arcelllx’s common stock (the “Shares”) for an aggregate purchase price of $100 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/0001193125-22-301426-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.